What is MTNB's market cap?

$1.17M, based on the Nov 4 close of $1.19.

Does Matinas BioPharma Holdings pay a dividend?

No regular cash dividend has been paid in the last year.

How much of MTNB is sold short?

49.4K shares, 0.5% of float, as of Oct 15, 2026.

What sector is MTNB in?

Healthcare, in the Pharmaceuticals industry.

NYSE American · MTNBHealthcarePharmaceuticals

Matinas BioPharma Holdings, Inc. (MTNB)

$1.19+4.39%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.19▼ 93.75% in range

Nov 4, 2025Low $1.14 · High $36.00Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Matinas BioPharma Holdings closed at $1.19 on Nov 4, up 4.39%, 96.7% below its 52-week closing high. Volume of 28.8K shares was 0.41× its 20-day average (below normal).

Split-adjusted performance: -60.5% over one month, -88.3% over six months, -94.1% over one year.

Short interest was 49.4K shares at the Oct 15 settlement, down 12.0% from the prior report (0.5% of float, 1.0 days to cover).

Market cap$1.2M979.5K shares

Revenue · quarter$0.00—

Diluted EPS$-3.15—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range1.14 – 36.00−96.7% from high

Volume28.8K0.41× 20-day avg

Volatility · 60d775.7%Annualised

Short % of float0.5%1.0 days to cover

Net cash$755.0KCash $761.0K

Next earnings—Not scheduled

Split-adjusted performance

1W −37.7%1M −60.5%3M −70.4%6M −88.3%YTD −86.5%1Y −94.1%3Y −99.2%5Y −99.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum4

Revenue growth—

Net margin—

Value (low P/E)—

Size1

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short49.4K−12.0% vs prior

Days to cover1.0Settled Oct 15

% of float0.5%

Short vol. 10d35.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
MTNBMatinas BioPharma Holdings	$1.19	+4.39%	−88.3%	—	—	—	$1.2M
JAGXJaguar Health	$0.4988	−10.53%	−97.6%	−58.9%	−1036.8%	—	$1.2M	Compare
ARTLArtelo Biosciences	$2.27	−5.42%	−90.9%	—	—	—	$1.2M	Compare
VBIOValion Bio	$0.5171	−2.60%	—	—	—	—	$1.1M	Compare
GOVXGeoVax Labs, Inc. New	$0.1680	+2.38%	−89.8%	−100.0%	—	—	$1.5M	Compare
ELABPMGC Holdings	$1.92	−1.03%	−91.0%	—	−225.1%	—	$1.6M	Compare
KPTIKaryopharm Therapeutics	$0.0729	−17.44%	−99.2%	−11.9%	−200.5%	—	$1.7M	Compare
KAPAKairos Pharma	$0.4897	−3.03%	−87.4%	—	—	—	$1.7M	Compare
OGENOragenics	$0.3720	+0.51%	−40.0%	—	—	—	$1.7M	Compare

News about Matinas BioPharma Holdings

All news →

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsGlobeNewswire Inc. · Sep 4, 2026▼ Negative

Quick answers

What does Matinas BioPharma Holdings do?: Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
What is MTNB's market cap?: $1.17M, based on the Nov 4 close of $1.19.
Does Matinas BioPharma Holdings pay a dividend?: No regular cash dividend has been paid in the last year.
How much of MTNB is sold short?: 49.4K shares, 0.5% of float, as of Oct 15, 2026.
What sector is MTNB in?: Healthcare, in the Pharmaceuticals industry.

About Matinas BioPharma Holdings

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

HQ: Bedminster, NJ2 employeesListed Jul 21, 2014matinasbiopharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology